ANL
NASDAQ
$11.98
Adlai Nortye Ltd (ANL)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $28.60 (+138.73%)
Market Cap
$317M
Beta (5Y)
1.07
Price Chart
Valuation
Market Cap$317M
P/S13.52
P/B38.65
Profitability
Total Revenue (TTM)$1.94M
Gross Profit (TTM)$5M
EBITDA-$42M
EPS-$1.14
Growth & Risk
Beta (5Y)1.07
Sharpe Ratio1.98